Methamphetamine (METH) causes long-term damage to dopaminergic neurons, with adolescent being lesssusceptible than young adult rats. Further, pretreatment with METH, beginning in adolescence, prevents thepersistent dopaminergic deficits caused when METH is administered during adulthood. Mechanismsunderlying these 'resistance' phenomena remain to be elucidated. One overarching hypothesis of thisprogram project is that events occurring during the early hours (i.e., < 8 h) after treatment (a period referredto herein as 'stage 1') and later (i.e., 24 - 72 h after treatment, referred to herein as 'stage 2') are bothnecessary to elicit this damage. Thus, this project will test the hypothesis that 'stage 2' events related tointracellular DA management are critical for the persistent dopaminergic deficits caused by METH,and that these events are absent in both adolescent rats and those treated with METH duringdevelopment.' This will be tested by investigating:1) the impact of development, and of METH treatment during adolescence, on the expression ofMETH-induced effects occurring during 'stage 2' including disruption of factors regulatingintraneuronal DA distribution and reactive species formation. For completeness, glial cell activation will beassessed as well.2) if targeted inhibition of 'stage 2' events prevents the persistent dopaminergic deficits caused byMETH. Pharmacological manipulations will be performed after the onset of 'stage 1' to determine if thesetreatments prevent 'stage 2' events and/or the long-term dopaminergic damage caused by METH.3) the impact of development, and of METH treatment during adolescence, on the expression ofMETH-induced effects occurring during 'stage 1' including effects on: 1) the vesicular monoaminetransporter-2; 2) the DA transporter and 3) reactive species formation. This will be accomplished eventhough the focus of this Project is 'stage 2,' as it is hypothesized that the factors occurring in 'stage 1'contribute to its expression.Importantly, several other factors contribute to the long-term deficits caused by METH and are focuses ofother projects in this PO1 application. This Project will focus on specific 'stage 1' and 'stage 2' factorsincluding those delineated above. Resulting data will be used to inform studies in Projects #2 and #3regarding potential targets of study, and visa versa. Identification of similar and dissimilar mechanisticfactors among the projects will provide insight into not only issues related to METH-induced neurotoxicity,but also degenerative disorders involving dopaminergic neurons such as Parkinson's disease.
Showing the most recent 10 out of 73 publications
